Indaptus Therapeutics, Inc.
INDP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.34
KIRA · Stoqly’s AI analyst, in plain words
- Indaptus Therapeutics, Inc. lost $20.8M in fiscal 2025.
Market cap
$388M
P/E
—
Revenue
—
Net income
−$20.8M
Free cash flow
—
Operating margin
—
Indaptus Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$20.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Indaptus Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Indaptus Therapeutics, Inc.
- CIK
- 0001857044
Indaptus Therapeutics, Inc. · INDP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$7.7M | −$14.3M | −$15.4M | −$15.0M | −$20.8M |
| Diluted EPS | −$1.89 | −$1.73 | −$1.83 | −$44.96 | −$21.58 |
| Cash | |||||
| Cash from operations | −$11.3M | −$13.1M | −$13.4M | −$12.3M | −$14.8M |
| Capital expenditure | $0.0M | — | — | — | — |
| Free cash flow | −$11.3M | — | — | — | — |
| Share count change | 110.3% | 102.0% | 1.7% | −96.0% | 189.2% |
| Debt and strength | |||||
| Cash and short-term investments | $39.1M | $26.4M | $13.4M | $5.8M | $8.5M |
| Shareholders' equity | $35.9M | $24.6M | $12.1M | $3.9M | $3.2M |
| Current ratio | 8.8x | 7.9x | 5.0x | 2.0x | 1.5x |
| Returns and quality | |||||
| Return on equity | −43.2% | −47.3% | −84.0% | −187.5% | −587.6% |
| Return on tangible equity | −21.5% | −58.2% | −127.7% | −380.8% | −661.5% |
| Altman Z'' | 11.3 | 6.0 | −7.9 | −36.8 | −40.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Indaptus Therapeutics, Inc. · INDP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.34 a share, the company is worth $388M.
Source: SEC EDGAR XBRL filings (CIK 0001857044). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.